Overview of the CDC cervical cancer (Cx3) study: An educational intervention of HPV testing for cervical cancer screening

Journal of Women's Health

Volumn 23, Issue 3, 2014, Pages 197-203

  Benard, Vicki B ^a   Saraiya, Mona ^a   Greek, April ^b   Hawkins, Nikki A ^a   Roland, Katherine B ^a   Manninen, Diane ^b   Ekwueme, Donatus U ^a   Miller, Jacqueline W ^a   Unger, Elizabeth R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SERODIAGNOSIS; UTERINE CERVIX CANCER; WART VIRUS; WART VIRUS TEST;

CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); EARLY DETECTION OF CANCER; FEMALE; HEALTH PERSONNEL; HUMANS; ILLINOIS; INTERVENTION STUDIES; MASS SCREENING; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; PATIENT EDUCATION AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; TIME FACTORS; UNITED STATES; VAGINAL SMEARS;

EID: 84896105455     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2013.4655     Document Type: Article

References (24)

1. Committee on Practice Bulletins-Gynecology. ACOG practice bulletin number 109: Cervical cytology screening. Obstet Gynecol 2009;114:1409-1420.
2. National Research Council. Clinical preventive services for women: Closing the gaps. Washington, DC: The National Academies Press, 2011.
3. Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;156:880-891.
4. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62: 147-172.
5. Bistoletti P, Sennfalt K, Dillner J. Cost-effectiveness of primary cytology and HPV DNA cervical screening. Int J Cancer 2008;122:372-376.
6. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008;100:308-320.
7. Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;87:2372-2381.
8. Roland KB, Soman A, Benard VB, Saraiya M. Human papillomavirus and Papanicolaou tests screening interval recommendations in the United States. American journal of obstetrics and gynecology. 2011;205:441-448.
9. Yabroff KR, Saraiya M, Meissner HI, et al. Specialty differences in primary care physician reports of papanicolaou test screening practices: A national survey, 2006 to 2007. Ann Intern Med 2009;151:602-611.
10. Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: What screening intervals are physicians recommending? Arch Intern Med 2010;170:977-985.
11. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol 2009;113:595-600.
12. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: A population-based study in routine clinical practice. Lancet Oncol 2011;12: 663-672.
13. Ryerson AB, Benard VB, Majors A. National Breast and Cervical Cancer Early Detection Program 1991-2002 national report: Summarizing the first 12 years of parnterships and progress against breast and cervical cancer. Atlanta: Centers for Disease Control and Prevention, 2003.
14. Roland KB, Benard VB, Saraiya M, Hawkins NA, Brandt H, Friedman AL. Assessing Cervical Cancer Screening Guidelines in Patient Education Materials. J Womens Health (Larchmt) 2009;18:5-12.
15. Flesch R. A new readability yardstick. J. Appl Psychol 1948;32:221-233.
16. Roland K, Benard VB, Greek A, Hawkins NA, Manninen D, SaraiyaM. Primary care provider practices and beliefs related to cervical cancer screening with the HPV test in Federally Qualified Health Centers. Prev Med 2013;57:419-425.
17. Hawkins NA, Benard VB, Greek A, Roland KB, Manninen D, Saraiya M. Patient knowledge and beliefs as barriers to extending cervical cancer screening intervals in Federally Qualified Health Centers. Prev Med 2013;57:641-645.
18. Saraiya M, Benard V, Greek A, Mannenin D, Massad LS, Unger E. HPV infection and cervical cytology among women in Federally Qualified Health Centers in Illinois. Podium presentation at the CDC National Cancer Conference, August 24-26, 2012 Washington, DC.
19. Coughlin SS, Breslau ES, Thompson T, Benard VB. Physician recommendation for papanicolaou testing among U.S. women, 2000. Cancer Epidemiol Biomarkers Prev 2005;14:1143-1148.
20. Baron RC, Melillo S, Rimer BK, et al. Intervention to increase recommendation and delivery of screening for breast, cervical, and colorectal cancers by healthcare providers a systematic review of provider reminders. Am J Prev Med 2010;38:110-117.
21. Curry WJ, Lengerich EJ, Kluhsman BC, et al. Academic detailing to increase colorectal cancer screening by primary care practices in Appalachian Pennsylvania. BMC Health Serv Res 2011;11:112.
22. U.S. Preventive Services Task Force Recommendation Statement: Screening for Cervical Cancer. 2012. Available at: www.uspreventiveservicestaskforce.org/ uspstf11/cervcancer/cervcancerrs.htm Accessed January 15, 2012.
23. Massad LS, Einstein MH, Huh WK, et al; 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013;121:829-846.
24. Bureau of Primary Healthcare. Available at: www.bphc.hrsa.gov/about/ Accessed January 10, 2013.